The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Anticancer Research

• Publication date

  2003-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 12926054
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells.

  2002cited by this paper
• NFκB Signaling in Posthypoxic Endothelial Cells: Relevance to E-Selectin Expression and Neutrophil Adhesion

  2001cited by this paper
• Induction of Systemic Neutrophil Response in Mice by Photodynamic Therapy of Solid Tumors¶

  2001cited by this paper
• Enhancement of tumor radioresponse by docetaxel: Involvement of immune system.

  2001cited by this paper
• Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors.

  2000cited by this paper
• Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide

  2000cited by this paper
• TNF-alpha, IL-4, and IFN-gamma regulate differential expression of P- and E-selectin expression by porcine aortic endothelial cells.

  2000cited by this paper
• Kinetics of the Different Steps during Neutrophil Migration through Cultured Endothelial Monolayers Treated with Tumour Necrosis Factor-α

  1999cited by this paper
• Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

  1999cited by this paper
• Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways.

  1999cited by this paper
• The tumour microcirculation as a target in cancer therapy: a clearer perspective

  1999cited by this paper
• Disruption of endothelial microfilaments selectively reduces the transendothelial migration of monocytes.

  1998cited by this paper
• Adhesion-dependent release of elastase from human neutrophils in a novel, flow-based model: specificity of different chemotactic agents.

  1998cited by this paper
• Comparison of Promoters for the Murine and Human P-selectin Genes Suggests Species-specific and Conserved Mechanisms for Transcriptional Regulation in Endothelial Cells*

  1998cited by this paper
• Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4.

  1998cited by this paper
• Each step during transendothelial migration of flowing neutrophils is regulated by the stimulatory concentration of tumour necrosis factor-alpha.

  1998cited by this paper
• Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.

  1997cited by this paper
• Effects of novel and conventional anti-cancer agents on human endothelial permeability: influence of tumour secreted factors.

  1997cited by this paper
• Regulation of E‐Selectin, P‐Selectin, and Intercellular Adhesion Molecule 1 Expression in Mouse Cremaster Muscle Vasculature

  1997cited by this paper
• Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins.

  1997cited by this paper
• L- and P-selectins, but not CD49d (VLA-4) integrins, mediate monocyte initial attachment to TNF-alpha-activated vascular endothelium under flow in vitro.

  1996cited by this paper
• Molecular mechanisms of leukocyte recruitment in the inflammatory process.

  1996cited by this paper
• Ischemia reperfusion injury in tumors: the role of oxygen radicals and nitric oxide.

  1995cited by this paper
• The interaction with tubulin of a series of stilbenes based on combretastatin A-4.

  1995cited by this paper
• Granulocyte-endothelium initial adhesion. Analysis of transient binding events mediated by E-selectin in a laminar shear flow.

  1993cited by this paper
• A simplified method for culture of endothelial cells and analysis of adhesion of blood cells under conditions of flow.

  1993cited by this paper
• Cytokine regulation of endothelial cell function.

  1992cited by this paper
• What is the evidence that tumors are angiogenesis dependent?

  1990cited by this paper
• Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin.

  1989cited by this paper
• Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4

  1989cited by this paper
• Tissue destruction by neutrophils.

  1989cited by this paper

• A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.

  2018cites this paper
• A dose‐escalation study of combretastatin A4‐phosphate in healthy dogs

  2018cites this paper
• Targeting PAM signaling pathway in the treatment of pancreatic ductal adenocarcinoma

  2017cites this paper
• Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?

  2015cites this paper
• New vascular disrupting agents in upper gastrointestinal malignancies.

  2014cites this paper
• Identification and Development of Vascular Disrupting Agents: Natural Products That Interfere with Tumor Growth

  2013cites this paper
• Treatment with the vascular disrupting agent combretastatin is associated with impaired AQP2 trafficking and increased urine output.

  2012cites this paper
• Study Of Focal Adhesion Kinase (Fak) Functions In Developmental Angiogenesis And Mammary Tumors Utilizing Knockin Technology

  2011cites this paper
• Disrupting established tumor blood vessels

  2010cites this paper
• Vascular disrupting agents (VDAs) in anticancer therapy.

  2010cites this paper
• Endotoxin-induced activation of equine digital vein endothelial cells: role of p38 MAPK.

  2009cites this paper
• AVE8062: a new combretastatin derivative vascular disrupting agent

  2009cites this paper
• Combination therapy studies with the vascular disruptive agentcombretastatin-a4-phosphate (CA4P)

  2009cites this paper
• Tumour targeting by microtubule-depolymerising vascular disrupting agents

  2007cites this paper
• Selective destruction of the tumour vasculature by targeting the endothelial cytoskeleton

  2007cites this paper
• Vascular disrupting agents.

  2007cites this paper
• Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure.

  2007cites this paper
• Disrupting tumour blood vessels

  2005cites this paper
• Antineoplastic agents. 509: synthesis of fluorcombstatin phosphate and related 3-halostilbenes(1).

  2005cites this paper
• Molecular targeting of drug delivery systems to cancer.

  2004cites this paper
• Valproic acid induces expression of neutrophil chemoattractants of the CXC chemokine family in endothelial cells.

  2004cites this paper